Can adalimumab (Humira) without concomitant corticosteroids cause Pneumocystis jirovecii pneumonia?

Can Humira Cause PCP Without Steroids?

Yes, adalimumab (Humira) monotherapy can cause Pneumocystis jirovecii pneumonia (PCP), though the risk is substantially lower than when combined with high-dose corticosteroids or other potent immunosuppressants.

Risk Stratification

The FDA explicitly warns that invasive fungal infections, including pneumocystosis, can occur in patients treated with adalimumab, and notes that most—but critically, not all—patients who developed serious infections were taking concomitant immunosuppressants such as corticosteroids 1. This indicates that adalimumab alone carries inherent PCP risk.

Documented Cases Without Steroids

• A multicenter case-control study of 17 RA patients who developed PCP on adalimumab found the median prednisolone dose at PCP onset was only 5.0 mg/day—well below the high-risk threshold 2
• PCP occurred at a median of 12 weeks after starting adalimumab, indicating early vulnerability even without high-dose steroids 2
• Three patients died in this cohort, underscoring the severity of PCP even in lower-risk scenarios 2

When Prophylaxis Is Required

High-dose glucocorticoid co-administration (≥20 mg prednisone-equivalent daily for ≥4 weeks) combined with adalimumab strongly warrants PCP prophylaxis 3, 4. This recommendation is endorsed by the American Thoracic Society and NCCN guidelines 4.

Additional High-Risk Scenarios Requiring Prophylaxis:

• Combination with T-cell-depleting agents (cyclophosphamide, alemtuzumab) 3
• Multiple concurrent immunosuppressants alongside adalimumab 3
• The 2022 EULAR guidelines recommend considering prophylaxis when high-dose glucocorticoids are combined with any immunosuppressant in autoimmune inflammatory rheumatic diseases 3

Prophylaxis Regimen When Indicated

First-line: Trimethoprim-sulfamethoxazole (TMP-SMX) 3

• One double-strength tablet (800/160 mg) daily, OR
• One single-strength tablet (400/80 mg) daily (better tolerated), OR
• One double-strength tablet three times weekly 3

Alternatives for TMP-SMX intolerance:

• Atovaquone 3
• Dapsone (after confirming normal G6PD) 3
• Aerosolized pentamidine 3

Duration:

• Continue throughout high-dose glucocorticoid therapy 3
• For T-cell-depleting agents: maintain for ≥2 months after therapy and until CD4 >200 cells/µL 3
• Discontinue when glucocorticoid dose falls below 20 mg/day and no other high-risk factors remain 3

Monitoring for Low-Risk Patients (Adalimumab Without High-Dose Steroids)

Since PCP can occur without concomitant high-dose steroids 2, vigilant clinical monitoring is essential:

• Educate patients on PCP symptoms: progressive dyspnea, dry cough, fever 3
• Maintain high index of suspicion for opportunistic infections, particularly in older patients with longer RA disease duration and more structural joint damage (identified risk factors in the adalimumab cohort) 2
• Early recognition is critical: Ground-glass opacities on chest CT without interlobular septal boundaries are characteristic 2
• Consider empiric antifungal therapy in at-risk patients who develop severe systemic illness, as antigen/antibody testing may be negative despite active infection 1

Common Pitfalls

• Assuming safety without steroids: The FDA boxed warning and case series demonstrate PCP can occur on adalimumab monotherapy 1, 2
• Delayed diagnosis: PCP developed at a median of 12 weeks after adalimumab initiation—maintain vigilance during the early treatment period 2
• Overlooking TMP-SMX toxicity: Approximately 20% of patients experience adverse events (rash, GI upset, cytopenias), with serious events like agranulocytosis occurring at 2.2% per patient-year 3, 4